Stand no: 16CT11
Tepnel Research Products & Services is using ICSE 2007 as a platform to launch a new range of Molecular Services. The new service offering will include a GxP quality genotyping service aimed at the clinical/research market; two new services based on Enzyme Linked ImmunoSorbent Assays (ELISA) and 2-D/3-D gel electrophoresis technology, which are specifically for companies developing, manufacturing and marketing biopharmaceutical products, and a new immunoassay development service for the pre-clinical and clinical phases of biopharmaceutical drug development.
All new services will be provided from Tepnel's new research facility in Livingston, Scotland, and will take advantage of the LIMS infrastructure of the new facility to provide an efficient and audit trailed process from sample receipt through to data handling/reporting.
The high throughput SNP (Single Nucleotide Polymorphism) genotyping service will meet the needs of both research and clinical market sectors via the use of a semi-automated approach based on miniaturised, fluorescent assays.
The ELISA services will be of particular interest to companies that are developing regulatory compliant pre-clinical toxicological studies, phase I-III bio-analytical and pharmacokinetic studies and ICH stability studies for large molecule biopharmaceuticals.
This immunoassay development service will offer development of regulatory compliant monoclonal and polyclonal bioassays that can be routinely used to support pre-clinical and clinical studies. The use of ELISA technology will provide a marked increase in the level of sensitivity required for biopharmaceutical drug products and will also provide support for bio-marker identification, elucidation and anti-drug information. The service will enable high throughput of samples in either 96 or 384 well formats.